- Home
- CNF vs DXR Comparison
CNF vs DXR Comparison
Compare CNF & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNF | DXR |
|---|---|---|
| Founded | 1999 | 1970 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.8M | 59.0M |
| IPO Year | 2018 | 1995 |
Fundamental Metrics
Financial Performance| Metric | CNF | DXR |
|---|---|---|
| Price | $2.84 | $10.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.1K | ★ 2.2K |
| Earning Date | 05-12-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $1,446,345.00 |
| Revenue This Year | $252.34 | $44,935.22 |
| Revenue Next Year | N/A | $74.79 |
| P/E Ratio | ★ N/A | $33.83 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.37 | $8.56 |
| 52 Week High | $24.00 | $14.76 |
Technical Indicators
Market Signals| Indicator | CNF | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 39.67 | 47.25 |
| Support Level | $2.57 | $9.76 |
| Resistance Level | $3.60 | $11.44 |
| Average True Range (ATR) | 0.15 | 0.44 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 16.25 | 43.17 |
Price Performance
Historical ComparisonAbout CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, the group generates all of its revenues in the PRC.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.